ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

ICER Posts Evidence Report on Obeticholic Acid for NASH 07/22/2020
AHRQ’s Registries User Guide Gets A New Edition 09/24/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership 04/10/2020
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Stanford Center for Health Education Launches Online Program… 08/11/2020
ICER Outlines Planned Review of Non-Alcoholic Steatohepatitis… 11/01/2019